Prescribing practices of second generation antipsychotics in hospital units;Pratiques de prescription hospitalière des antipsychotiques de seconde génération

Therapie

Volumn 60, Issue 6, 2005, Pages 567-572

  Boulin, Mathieu ^a,b   Maach, Souad ^a   Serot, Dominique ^a   Martin, Pascale ^a   Alizon, Brigitte ^a   Vailleau, Jean Louis ^a  

^a Service Pharmacie   (France)

^b Service Pharmacie   (France)

Author keywords

Guidelines; Prescribing practices; Second generation antipsychotics

Indexed keywords

AMISULPRIDE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL PRACTICE; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT INDICATION;

EID: 33645757777     PISSN: 00405957     EISSN: 00405957     Source Type: Journal    
DOI: 10.2515/therapie:2005079     Document Type: Article

References (17)

1. Fédération Française de Psychiatrie. Conférence de Consensus. Schizophrénies débutantes : diagnostics et modalités thérapeutiques; Paris; 23 et 24 janvier 2003 [online]. Available from URL: http://psydocfr.broca.inserm.fr/ conf&rm/conf/confschizo2/recommlongues.htm. [Accessed 2004 Oct 20]
2. American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154 Suppl. 4: 1-63
3. Sartorius N, Fleischhacher W, Gjerris A, et al. The usefulness and use of second generation antipsychotic medications. Curr Opin Psychiatry 2002; 15 Suppl. 1: S1-S51
4. National Health Service. National Institute for Clinical Excellence (NICE). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance 2002; No. 43: 1-21 [online]. Available from URL: http://www.nice.org.uk/pdf/ANTIPSYCHOTIC finalguidance.pdf [Accessed 2004 Oct 20]
5. Bret P, Bonnet F, Bret MC, et al. Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for amisulpride, clozapine, olanzapine and risperidone. Encephale 2002; 28: 329-42
6. Roberge C, Dauvillier JM, Welter JA, et al. Enquête prospective d'opinion de la rispéridone. Pharm Hosp 1999; 34: 43-8
7. Hamel B, Courtet P, Vergnes C, et al. Prescription hospitalière de la rispéridone et de l'olanzapine : enquête et recommandations. J Pharm Clin 2000; 19: 187-93
8. CIM-10. Classification internationale des maladies. Dixième révision. Chapitre V : troubles mentaux et troubles du comportement. Paris: Organisation Mondiale de la Santé et Masson, 1992
9. Vidal. Dictionnaire des spécialités. Paris: Vidal, 2004 [online]. Available from URL: http:/vidalpro.net. [Accessed 2005 Apr 4]
10. Agence Nationale pour le Développement de l'Evaluation Médicale (ANDEM). Prescription des neuroleptiques : recommandations et références médicales. Paris: ANDEM, 1995: 2 [online]. Available from URL: http://agmed.sante. gouv.fr/htm/5/5200c.htm#31.neurol. [Accessed 2005 Apr 5]
11. Agence Française de Sécurité Sanitaire des Produits de Santé (Afssaps). Information importante de pharmacovigilance concernant le risque de mortalité et d'accidents vasculaires cérébraux chez les patients âgés atteints de démence traités par olanzapine (Zyprexa®, Zyprexa Velotab®) pour des troubles psychotiques et/ou troubles du comportement. Lettre aux prescripteurs du 9 mars 2004 [online]. Available from URL: http://agmed.sante.gouv.fr/htm/10/ filltrpsc/indltrps.htm. [Accessed 2004 Oct 20]
12. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation and psychosis of demen-tia. J Clin Psychiatry 2003; 64: 134-43
13. Tariot PN, Profenno LA, Ismail MS. Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry 2004; 65 Suppl. 11: 11-5
14. Herrmann N, Mamdami M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113-5
15. Mowat D, Fowlie D, MacEwan T. Committee on Safety of Medicines warning on atypical psychotics and stroke may be detrimental for dementia [letter]. BMJ 2004; 328: 1262
16. Menzin J, Boulanger L, Friedman M, et al. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003; 54: 719-23
17. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparison of monotherapy with polypharmacy and augmentation. Curr Med Chem 2004; 11: 313-27